Effect of cTBS on Startle and TMS-evoked BOLD
ConditionAnxiety
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-50
SponsorUniversity of Pennsylvania
About this trial
The right dorsolateral prefrontal cortex (dlPFC) is increasingly being targeted with transcranial magnetic stimulation (TMS) to reduce anxiety expression; however, there is little mechanistic evidence supporting an optimized treatment protocol. Thus, the objective of the current project is to develop an interleaved TMS/fMRI that can assess the effect of neuromodulatory (potentially therapeutic) TMS protocols on neural and behavioral measures related to anxiety expression. PUBLIC HEALTH RELEVANCE: These results will yield direct evidence that 1 Hz and cTBS modulate brain activity associated with anxiety expression and regulation, thus informing novel TMS based anxiety treatments.
Eligibility criteria
Qualifiers
Able to give their consent
Right-handed
Individuals receiving therapy for anxiety must be stable on their regimen for at least 4 weeks prior to study enrollment.
Disqualifiers
Non-english speaking
Any significant medical or neurological problems
Current or past non-anxiety-related psychiatric comorbidity, active or history of active suicidal ideation
Alcohol/drug problems in the past year or lifetime alcohol or drug dependence
Trial design
Treatments tested in this trial
- Active TMS
- Sham TMS
Treatment groups
140 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov